Taiho Pharmaceutical Co. Ltd. has embarked on a five-year plan to expand into Western markets using its late-stage chemotherapeutics as a beachhead for the company's pipeline of novel cancer candidates, including at least one that will begin Phase I testing in the U.S. next year.

Though perhaps better known in Japan for its energy drinks, including flagship brand Tiovita, Taiho also has established a strong commercial presence domestically based on the success of its 5-FU-based chemotherapies.